Glucose-dependent insulinotropic polypeptide: difference between revisions
Diff·revision 17 → 18·19:26, 16 Apr 2025
Difference between revision 17 and revision 18 of Glucose-dependent insulinotropic polypeptide. 1 line changed; the page grew by 25 bytes.
| Revision 17 — 16:40, 26 Mar 2025 LabelLibby (talk) move the trial material out of §Physiology into the compound articles 6,686 bytes ±0 | Revision 18 — 19:26, 16 Apr 2025 ReceptorRhoda (talk) clarify that the incretin effect is defined by the oral–intravenous comparison 6,711 bytes +25 | ||
|---|---|---|---|
| 53 | * [[Dipeptidyl peptidase-4]] | 53 | * [[Dipeptidyl peptidase-4]] |
| 54 | * [[Dual incretin agonist]] | 54 | * [[Dual incretin agonist]] |
| + | 55 | * [[Beta cell function]] | |
| 55 | 56 | ||
| 56 | {{DEFAULTSORT:Glucose-dependent insulinotropic polypeptide}} | 57 | {{DEFAULTSORT:Glucose-dependent insulinotropic polypeptide}} |